Why Industry Should Model and De-Risk its Pharma Supply Chains
This article was originally published in The Gold Sheet
Executive Summary
As new biotech drugs come on the market, they will require supply chains that are more agile but less efficient. AstraZeneca’s MedImmune biologics unit looks to boost agility by modeling its supply chains and using a neural network to de-risk them.